Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
(European Society for Medical Oncology) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Study